DZ2077A1 - Procédé nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites. - Google Patents

Procédé nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites.

Info

Publication number
DZ2077A1
DZ2077A1 DZ960121A DZ960121A DZ2077A1 DZ 2077 A1 DZ2077 A1 DZ 2077A1 DZ 960121 A DZ960121 A DZ 960121A DZ 960121 A DZ960121 A DZ 960121A DZ 2077 A1 DZ2077 A1 DZ 2077A1
Authority
DZ
Algeria
Prior art keywords
dosage forms
novel method
produced
formulating solid
solid dosage
Prior art date
Application number
DZ960121A
Other languages
English (en)
French (fr)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515624.6A external-priority patent/GB9515624D0/en
Priority claimed from GBGB9606684.0A external-priority patent/GB9606684D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2077A1 publication Critical patent/DZ2077A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ960121A 1995-07-29 1996-07-27 Procédé nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites. DZ2077A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515624.6A GB9515624D0 (en) 1995-07-29 1995-07-29 Novel process
GBGB9606684.0A GB9606684D0 (en) 1996-03-29 1996-03-29 Novel process

Publications (1)

Publication Number Publication Date
DZ2077A1 true DZ2077A1 (fr) 2002-07-22

Family

ID=26307485

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ960121A DZ2077A1 (fr) 1995-07-29 1996-07-27 Procédé nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites.

Country Status (25)

Country Link
EP (1) EP0841902A2 (ru)
JP (1) JPH11510493A (ru)
KR (1) KR19990035972A (ru)
CN (1) CN1196677A (ru)
AP (1) AP858A (ru)
AR (1) AR004178A1 (ru)
AU (1) AU716961B2 (ru)
BG (1) BG102266A (ru)
BR (1) BR9609804A (ru)
CA (1) CA2228048A1 (ru)
CZ (1) CZ24798A3 (ru)
DZ (1) DZ2077A1 (ru)
EA (2) EA000740B1 (ru)
HU (1) HUP9900521A3 (ru)
IL (1) IL122897A0 (ru)
MA (1) MA23953A1 (ru)
MX (1) MX9800809A (ru)
NO (1) NO980384L (ru)
NZ (1) NZ315632A (ru)
OA (1) OA10659A (ru)
PL (1) PL325242A1 (ru)
SK (1) SK11098A3 (ru)
TR (1) TR199800156T1 (ru)
UY (1) UY24297A1 (ru)
WO (1) WO1997004750A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
AU2742102A (en) 2000-12-14 2002-06-24 Ortho Mcneil Pharm Inc Steroid hormone products and methods for preparing them
US20070202179A1 (en) * 2004-04-09 2007-08-30 FAULKNER Patrick Low Dose Pharmaceutical Products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
JPS5970614A (ja) * 1982-10-14 1984-04-21 Asahi Chem Ind Co Ltd 微量主薬系湿式固形製剤方法
US4898736A (en) * 1988-03-09 1990-02-06 Merck & Co., Inc. Method for tablet preparation
ES2219636T3 (es) * 1989-04-13 2004-12-01 Beecham Group P.L.C. Nuevos compuestos.
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.

Also Published As

Publication number Publication date
NO980384D0 (no) 1998-01-28
JPH11510493A (ja) 1999-09-14
AP9801170A0 (en) 1998-01-31
SK11098A3 (en) 1998-07-08
BR9609804A (pt) 1999-07-06
HUP9900521A2 (hu) 1999-06-28
AR004178A1 (es) 1998-11-04
IL122897A0 (en) 1998-08-16
WO1997004750A3 (en) 1997-03-27
EA199800179A1 (ru) 1998-10-29
EP0841902A2 (en) 1998-05-20
EA000740B1 (ru) 2000-02-28
CA2228048A1 (en) 1997-02-13
BG102266A (en) 1998-10-30
NZ315632A (en) 1999-11-29
AP858A (en) 2000-07-12
EA199901055A1 (ru) 2000-06-26
MX9800809A (es) 1998-04-30
WO1997004750A2 (en) 1997-02-13
CN1196677A (zh) 1998-10-21
MA23953A1 (fr) 1997-04-01
AU716961B2 (en) 2000-03-09
TR199800156T1 (xx) 1998-04-21
KR19990035972A (ko) 1999-05-25
NO980384L (no) 1998-03-26
OA10659A (en) 2002-09-18
AU6738496A (en) 1997-02-26
PL325242A1 (en) 1998-07-06
HUP9900521A3 (en) 2001-04-28
UY24297A1 (es) 1997-01-23
CZ24798A3 (cs) 1998-06-17

Similar Documents

Publication Publication Date Title
MA26410A1 (fr) Formulations pharmaceutiques et procede pour leur production.
HK1019858A1 (en) Process for forming solid oral dosage forms of valsartan.
TR199600792A2 (tr) Dihaloazolopirimidinlerin hazirlanmasina yönelik proses.
MA23143A1 (fr) Procede pour la preparation de compositions vaccinantes .
FR2685916B1 (fr) Inhibiteurs mixtes de la no synthase et de la cyclooxygenase, ainsi qu'un procede pour leur preparation.
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
HUP0000214A3 (en) Alpha-substituted benzenesulphonamido hydroxamic acids, process for their preparation and pharmaceutical compositions containing them
EP0837927A4 (en) MONOCLONAL MONKEY ANTIBODIES AGAINST HUMANE B7.1 AND / OR B7.2 ANTIGEN, PRIMATIZED DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
HUP9602511A3 (en) Aryl-diazinone derivatives, pharmaceutical compositions containing them, and process for producing all these
NL300109I1 (nl) Kristalmodificatie van CDCH, werkwijze voor de bereiding ervan en van farmaceutische preparaten die deze modificaties bevatten.
MA23395A1 (fr) Procede de preparation de nouvelles formulations
NO981800D0 (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
ZA965712B (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds.
FR2707087B1 (fr) Nouveau procédé de préparation de l'ergothionéine.
DZ1910A1 (fr) Nouvelles streptogramines et procédé de préparation de streptogramines par mutasynthèse.
HUP9601034A3 (en) Aryl-alkyl-pyridazinone compounds, process for producing them, and pharmaceutical compositions containing them
FR2707486B1 (fr) Procédé de déformation permanente des matières kératiniques.
FR2714063B1 (fr) Procédé de préparation de collagène à partir de cnidaires, et compositions obtenues utilisables en cosmétique.
DZ2077A1 (fr) Procédé nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites.
HU9602763D0 (en) Novel isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
FR2700956B1 (fr) Composition cosmetique et pharmaceutique et procede pour sa preparation.
HUT73975A (en) Substituted benzol-sulfonyl-ureas and-thioureas, process for producing them, pharmaceutical compositions containing them and their use